Uncategorized

Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026

admin / October 14, 2026

Utrecht, Netherlands – 14 October 2026: Sapreme Therapeutics (“Sapreme” or the “Company”), a biotechnology company developing next-generation RNA therapeutics for […]

Uncategorized

Sapreme Development B.V. to become Sapreme Therapeutics B.V.

admin / May 27, 2026

As our company continues to evolve, we’re excited to announce that effective June 1st, 2026, Sapreme Development B.V. will become

Uncategorized

Sapreme Appoints CEO, BoD Chair and SAB to Advance Development of Next-Generation RNA Therapeutics for Genetically Driven Diseases

admin / May 28, 2024

Bilthoven, The Netherlands, May 28, 2024 – Sapreme, a biotechnology company focused on developing next-generation RNA therapeutics for patients with